Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes
Launched by NOVO NORDISK A/S · Oct 21, 2010
Trial Information
Current as of May 17, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients diagnosed with type 2 diabetes
- • Patients having recently started (for less than one week) or starting liraglutide (Victoza®) treatment
- Exclusion Criteria:
- • Hypersensitivity (allergy) to liraglutide or to any of the excipients
- • Patient is participating in a clinical trial at the inclusion
- • Type 1 diabetes
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris La Défense Cedex, , France
Patients applied
Trial Officials
Global Clinical Registry (GCR, 1452), Medical Advisor
Study Director
Novo Nordisk A/S
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials